Results 241 to 250 of about 134,892 (289)

Perspectives on the interpretation of mitochondrial responses during skeletal muscle disuse‐induced atrophy

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Common human and rodent muscle disuse models and associated changes in skeletal muscle mitochondrial function; respiration, redox stress and apoptotic cell death. I–V, complexes I–V; ETF, electron transfer flavoprotein; Q, Q cycle; C, cytochrome c; Pi, inorganic phosphate; ROS, reactive oxygen species.
Luca J. Delfinis   +2 more
wiley   +1 more source

Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes

open access: yes
Patzke S   +9 more
europepmc   +1 more source

Five Cellular Genes as Candidates for Cervical Adenocarcinoma Molecular Markers. [PDF]

open access: yesCancers (Basel)
García-Montoya IA   +7 more
europepmc   +1 more source

Exosomes, autophagy, and cancer: A complex triad

open access: yesInternational Journal of Cancer, Volume 157, Issue 3, Page 405-415, 1 August 2025.
Abstract Cancer remains one of the leading causes of death worldwide. Despite remarkable progress in prevention, diagnosis, and therapy, the incidence of certain types of cancer persists, urging the identification of clinically relevant biomarkers and the development of novel therapeutic strategies to improve clinical outcomes and overcome treatment ...
María Guerra‐Andrés   +2 more
wiley   +1 more source

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

open access: yesInternational Journal of Cancer, Volume 157, Issue 3, Page 534-548, 1 August 2025.
What's new? Tumor necrosis factor (TNF) can promote tumor resistance to immune checkpoint inhibitors (ICIs), which are now the standard treatment for advanced melanoma patients. Here, in an advanced melanoma patient cohort, TNF was investigated for a possible predictive relationship with ICI response. Assessments show that after 12 weeks of ICI therapy,
Mathieu Virazels   +18 more
wiley   +1 more source

TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

open access: yesHematological Oncology, Volume 43, Issue 4, July 2025.
ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy